- Active not recruitingPHASE1
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
This study looks at a new drug called XL092 for advanced solid tumours like kidney, breast, prostate, or bowel cancer. Researchers are testing it alone and with other drugs (Atezolizumab, Avelumab) to see if it's safe, how it works, and if it can help slow down or shrink tumours.
For: Neoplasm Malignant · Renal Cell Carcinoma · Hormone Receptor Positive Breast CarcinomaUnited States · Australia · Belgium - Active not recruitingPHASE3
Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
This study is for people with advanced kidney cancer (non-clear cell type) that hasn't spread too widely. It compares a new combination of drugs (XL092 + nivolumab) with a standard treatment (sunitinib) to see which works better. Participants haven't had prior cancer medicine for their advanced kidney cancer.
For: Non-Clear Cell Renal Cell CarcinomaUnited States · Argentina · Australia - Active not recruitingPHASE3
Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer
This study compares two treatments, XL092 (plus atezolizumab) and regorafenib, for advanced bowel cancer that has spread. It's for people whose cancer hasn't responded well to previous common treatments. We want to see which treatment works better to control the cancer.
For: Colorectal CancerUnited States · Australia · Belgium